Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients
NCT04480294Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-5091 in Chronic Hepatitis B (CHB) (10 arms), sponsored by Hengrui. Primary endpoints: Incidence and severity of treatment-related adverse events at 56 days, Maximum Plasma Concentration and 6 more. Status: unknown.
02
Drugs
HRS-5091
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04480294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480294.